Want to see JP:4539 full AI Analyst Report?
Top Page
Nippon Chemiphar Co., Ltd.
(4539)
Select Model
Select Model
Rating:46Neutral
Price Target:
¥1,505.00
▼(-5.05% Downside)
Action:Reiterated
Date:10/10/26
The score is held back primarily by pressured cash generation (recurring negative free cash flow and volatile operating cash flow) and inconsistent profitability despite strong revenue recovery. Technicals also remain weak with the stock trading below key moving averages and negative MACD. Valuation is mixed: the negative P/E limits comparability, partly offset by a ~3.26% dividend yield.
Positive Factors
Revenue Recovery
The sharp revenue recovery indicates renewed demand and improved commercial traction after the prior-year decline. If the rebound persists, a larger sales base can support operating leverage, broader product reach, and more resources for maintaining the company’s prescription-drug franchise.
Negative Factors
Weak Cash Generation
Repeated free-cash-flow deficits reduce confidence that reported earnings consistently convert into funding for the business. Volatile operating cash flow can constrain investment, debt reduction, and shareholder distributions, leaving less flexibility if operating conditions weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The sharp revenue recovery indicates renewed demand and improved commercial traction after the prior-year decline. If the rebound persists, a larger sales base can support operating leverage, broader product reach, and more resources for maintaining the company’s prescription-drug franchise.
Read all positive factors
Nippon Chemiphar Co., Ltd. (4539) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.57B
Dividend Yield3.24%
Average Volume (3M)2.08K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue Growth0.60%
EPS Growth-131.22%
CountryJP
Employees878
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)109.50
Shares Outstanding4,261,420
10 Day Avg. Volume2,510
30 Day Avg. Volume2,083
Financial Highlights & Ratios
PEG Ratio-0.99
Price to Book (P/B)0.33
Price to Sales (P/S)0.19
P/FCF Ratio-27.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nippon Chemiphar Co., Ltd. Business Overview & Revenue Model
Company Description
Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a global pharmaceutical entity engaged in the research, production, marketing, and sale of ethical drugs and diagnostic agents. Its diagnostic product lineup features the IgE NC kit, which...
How the Company Makes Money
Nippon Chemiphar makes money primarily by selling pharmaceutical products. Its core revenue stream is domestic sales of prescription medicines to wholesalers and distributors that supply hospitals, clinics, and pharmacies; revenue is recognized ba...
Nippon Chemiphar Co., Ltd. Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
56
Neutral
Cash Flow
33
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.82B | 33.09B | 32.57B | 30.75B | 31.56B | 32.51B |
| Gross Profit | 8.93B | 8.40B | 8.75B | 7.74B | 8.19B | 9.07B |
| EBITDA | 2.01B | 2.00B | 1.83B | 1.40B | 2.10B | 2.68B |
| Net Income | 395.00M | 198.00M | 294.00M | -180.00M | 339.00M | 700.00M |
Balance Sheet | ||||||
| Total Assets | 52.68B | 49.98B | 49.85B | 49.55B | 48.57B | 49.45B |
| Cash, Cash Equivalents and Short-Term Investments | 9.69B | 5.34B | 7.02B | 9.20B | 10.53B | 11.64B |
| Total Debt | 19.02B | 16.58B | 18.06B | 16.98B | 15.23B | 14.79B |
| Total Liabilities | 33.76B | 30.46B | 30.68B | 31.08B | 30.03B | 30.95B |
| Stockholders Equity | 18.92B | 19.51B | 19.17B | 18.46B | 18.53B | 18.50B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -231.00M | -1.86B | -2.34B | -1.93B | 1.07B |
| Operating Cash Flow | 0.00 | 620.00M | -265.00M | 296.00M | -916.00M | 1.80B |
| Investing Cash Flow | 0.00 | -661.00M | -1.66B | -3.14B | -394.00M | 35.00M |
| Financing Cash Flow | 0.00 | -1.67B | -305.00M | 1.45B | 144.00M | -793.00M |
Nippon Chemiphar Co., Ltd. Technical Analysis
Negative
1585.00
Price Trends
1563.82
Negative
1577.10
Negative
1623.57
Negative
Market Momentum
-6.89
Positive
45.64
Neutral
27.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4539, the sentiment is Negative. The current price of 1585 is above the 20-day moving average (MA) of 1554.70, above the 50-day MA of 1563.82, and below the 200-day MA of 1623.57, indicating a bearish trend. The MACD of -6.89 indicates Positive momentum. The RSI at 45.64 is Neutral, neither overbought nor oversold. The STOCH value of 27.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4539.
Nippon Chemiphar Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | ¥8.97B | 11.43 | ― | 2.98% | 0.98% | 69.36% | |
67 Neutral | ¥38.37B | 12.22 | ― | 3.01% | -2.83% | 65.69% | |
64 Neutral | ¥18.50B | 8.22 | ― | 4.28% | 2.29% | ― | |
61 Neutral | ¥13.07B | 19.07 | ― | 1.28% | 13.30% | 66.38% | |
59 Neutral | ¥10.34B | 30.22 | ― | 1.17% | 25.89% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | ¥5.57B | -44.93 | ― | 3.27% | 0.60% | -131.22% |
* Healthcare Sector Average
JP:4539
Nippon Chemiphar Co., Ltd.
1,530.00
-30.45
-1.95%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
300.00
9.45
3.25%
JP:4524
Morishita Jintan Co., Ltd.
2,184.00
89.09
4.25%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,105.00
-11.32
-0.53%
JP:4574
Taiko Pharmaceutical Co., Ltd.
257.00
-38.00
-12.88%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,329.00
130.97
10.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.